With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines.
This shift is reflected in the growing drug-delivery market, which is projected to reach $410 billion. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle(TM) platform as key components of a wider industry shift toward scalable nanotechnology-driven drug delivery and AI-enhanced biomedical infrastructure. The company’s approach centers on leveraging platform technologies that may serve multiple therapeutic applications across oncology and rare disease markets rather than depending on a solitary drug candidate.
Oncotelic is among several companies, including CytoDyn Inc. (OTCQB: CYDY), Revolution Medicines Inc. (NASDAQ: RVMD), Moderna Inc. (NASDAQ: MRNA) and Sarepta Therapeutics Inc. (NASDAQ: SRPT), that are developing scalable biotechnology platforms designed to support multiple therapeutic programs across diverse disease areas. This platform model allows companies to reduce risk and accelerate development timelines by applying a proven delivery mechanism to different drugs.
The implications for the industry are significant. As traditional drug discovery becomes more expensive and less predictable, platform technologies offer a way to extend the lifecycle of existing drugs and improve patient outcomes. For investors, companies with robust platforms may present more attractive opportunities due to their potential for multiple revenue streams and lower development costs. The focus on drug delivery also addresses a critical need in oncology: many promising therapeutics fail not because they are ineffective, but because they cannot be delivered effectively to tumors or cause severe side effects.
Oncotelic’s Deciparticle(TM) platform, for instance, is designed to enhance the delivery of nucleic acid therapeutics, a class of drugs that includes gene therapies and RNA-based treatments. By improving delivery, the platform could unlock the potential of these therapies for a wider range of diseases. Similarly, Sapu003 is being developed as a treatment for various cancers, leveraging the company’s expertise in drug delivery.
The market’s trajectory toward $410 billion underscores the growing recognition of drug delivery as a critical component of therapeutic success. As more companies adopt platform-based approaches, the industry may see a shift in how drugs are developed and commercialized. This could lead to more efficient use of R&D budgets, faster time-to-market for new therapies, and ultimately, better treatment options for patients.
